Pharmala Biotech【MDMA】銘柄情報

Pharmala Biotech Holdings Inc (MDMA) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.14

( 3.70% )

買値

0.135

売値

0.145

出来高

32,163

平均取引量 (3 か月)

$ 208,832

財務取引量

0.14 日の範囲 0.14

0.085 52 週間の範囲 0.195

時価総額

15.244M

企業価値

14.667M

前日終値

0.135

始値

0.14

時刻

4000

0.14

最終取引時間

VWAP

歳入

889.57k

純利益

-1.63M

発行済株式数

108,887,215

浮動株比率 (%)

90.27%

機関投資家保有比率 (%)

配当利回り

PER

-9.03

株価売上高倍率 (PSR)

17.14

1 株当たり利益 (EPS)

-0.02

ベータ

0.75

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headqu... Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

pharmala.ca

本社

Vancouver, Canada

設立

Pharmala Biotech Holdings Inc is listed in the Healthcare sector of the Canadian Securities Exchange with ticker MDMA. The last closing price for Pharmala Biotech was $0.14. Over the last year, Pharmala Biotech shares have traded in a share price range of $ 0.085 to $ 0.195.

Pharmala Biotech currently has 108,887,215 shares in issue. The market capitalisation of Pharmala Biotech is $15.24 million. Pharmala Biotech has a price to earnings ratio (PE ratio) of -9.03.

PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset

TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a...

Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement

The psychedelics market continues to expand rapidly as researchers gain a deeper understanding of its potential therapeutic benefits. Today, a...

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF...

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President...

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF...

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF...

PharmAla Issues Q2 Financial Statements and Grants Options

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”...

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF...

Cortexa Advances Commercialisation of MDMA Supply in Australia

MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading...

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

TORONTO, March 03, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0.14	0.145	0.135	48899	0.13958197	CS
4	-0.01	-6.66666666667	0.15	0.16	0.13	65173	0.14198399	CS
12	0.04	40	0.1	0.195	0.09	221985	0.16021282	CS
26	0.03	27.2727272727	0.11	0.195	0.085	156760	0.14159585	CS
52	0.04	40	0.1	0.195	0.085	170305	0.12894175	CS
156	-0.245	-63.6363636364	0.385	0.4	0.065	308342	0.17832197	CS
260	-0.3	-68.1818181818	0.44	0.54	0.02	436584	0.18472387	CS

MDMA - Frequently Asked Questions (FAQ)

What is the current Pharmala Biotech Holdings Inc share price?

The current share price of Pharmala Biotech Holdings Inc is $ 0.14

How many Pharmala Biotech Holdings Inc shares are in issue?

Pharmala Biotech Holdings Inc has 108,887,215 shares in issue

What is the market cap of Pharmala Biotech Holdings Inc?

The market capitalisation of Pharmala Biotech Holdings Inc is CAD 15.24M

What is the 1 year trading range for Pharmala Biotech Holdings Inc share price?

Pharmala Biotech Holdings Inc has traded in the range of $ 0.085 to $ 0.195 during the past year

What is the PE ratio of Pharmala Biotech Holdings Inc?

The price to earnings ratio of Pharmala Biotech Holdings Inc is -9.03

What is the cash to sales ratio of Pharmala Biotech Holdings Inc?

The cash to sales ratio of Pharmala Biotech Holdings Inc is 17.14

What is the registered address of Pharmala Biotech Holdings Inc?

The registered address for Pharmala Biotech Holdings Inc is 1055 West Georgia Street, Vancouver, British Columbia, V6E 4N7

What is the Pharmala Biotech Holdings Inc website address?

The website address for Pharmala Biotech Holdings Inc is pharmala.ca

Which industry sector does Pharmala Biotech Holdings Inc operate in?

Pharmala Biotech Holdings Inc operates in the Biotechnology & Life Sciences sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Pharmala Biotech Holdings Inc (MDMA)

Pharmala Biotech Holdings Inc (MDMA) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Pharmala Biotech Holdings Inc について

MDMA 最新ニュース

PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset

Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

PharmAla Issues Q2 Financial Statements and Grants Options

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

Cortexa Advances Commercialisation of MDMA Supply in Australia

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

PharmAla Issues Q2 Financial Statements and Grants Options

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

Cortexa Advances Commercialisation of MDMA Supply in Australia

MDMA - Frequently Asked Questions (FAQ)

MDMA 取引

MDMA Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する